Kathryn Phillips, PhD

Professor

Kathryn A. Phillips, PhD, is Professor of Health Economics and Health Services Research in the Department of Clinical Pharmacy at UCSF. A leader in the application of new technologies to improve healthcare, she is the Founding Director of the UCSF Center for Translational and Policy Research on Precision Medicine (TRANSPERS). She is a core faculty member in the UCSF Philip R. Lee Institute for Health Policy Studies and UCSF Helen Diller Family Comprehensive Cancer Center, and is affiliated with the Institute for Human Genetics, Department of Epidemiology and Biostatistics, Baker Computational Health Sciences Institute, and Global Health Sciences. She is the Founding Editor-in-Chief, Health Affairs Scholar: Emerging and Global Health Policy.

Kathryn focuses on the value of new technologies and how to most effectively and efficiently implement them into health care. Her core specialty is precision medicine — a new era of healthcare where medical interventions can be tailored to individual patients based on their unique genetic make-up. Her work spans multiple disciplines, including basic, clinical and social sciences, and brings together leading experts in academia, industry, healthcare, payers, and government. Her pioneering research on the application of health services research to personalized medicine has revealed insights on how to bridge the gap between emerging technologies and their use in the clinic. Kathryn led one of the earliest studies on the societal implications of pharmacogenomics, underscoring its potential to reduce the incidence of adverse drug reactions (JAMA, 2001). Kathryn has also conducted seminal work on HIV, as her analysis of HIV home testing informed the FDA’s decision to approve the first home collection HIV test (New England Journal of Medicine, 1995).

Kathryn has published ~200 peer-reviewed articles in major journals including JAMA, New England Journal of Medicine, Science, and Health Affairs and has been repeatedly named as being in the top 2% of authors for career-long citations in her field and in the top 100,000 of all researchers (Baas, 2021; Ioannidis 2020). She has had continuous funding from NIH as a Principal Investigator for 3 decades and was awarded a 5-year, $5M NIH grant to examine payer coverage and economic value for emerging genomic technologies. Kathryn serves on the editorial boards for Health Affairs and Value in Health and previously for JAMA Internal Medicine. She is a member of the National Academy of Medicine Roundtable on Genomics and Precision Health and served on a National Academy of Medicine consensus committee (2024-2025); and has served on the governing Board of Directors for GenomeCanada and as an advisor to the FDA, CDC, President’s Council of Advisors on Science and Technology, and the White House Office of Science and Technology. She has also served as an advisor to many diagnostics, sequencing, and pharmaceutical companies as well as venture capitalists. Kathryn is Chair of the Global Economics and Evaluation of Clinical Sequencing Working Group, and a member of one of the three evidence review committees for the Institute for Clinical and Economic Review (ICER). Her work has been quoted by the Washington Post, Wall Street Journal, New York Times, CNBC, Reuters, Newsweek, and other major news outlets.


Disclosures: Current
ICER: Dr. Phillips receives honoraria from the California Technology Assessment Forum (CTAF), which is an independent appraisal committee for the Institute for Clinical and Economic Review (ICER).

Illumina, Inc.: Dr. Phillips receives consulting from Illumina for support of the Global Economics and Evaluation of Clinical Genomics Sequencing Working Group (https://www.geecsecon.org/).

Disclosures: Completed in past 3 years
Precision Health Research, Singapore (PRECISE). Dr. Phillips is a member of the Health Economist Expert Network for PRECISE. PRECISE is a central entity set up to coordinate the government effort to implement Phase II of Singapore's 10-year National Precision Medicine strategy. (ended 2022)

Philips Healthcare. Dr Phillips was a member of a one-time meeting of the North American Oncology Advisory Community. Philips Healthcare provides healthcare solutions for diagnostic, treatment, and preventive care. (ended 2021)

Avia Health. Dr. Phillips was a consultant to Avia Health, which focuses on digital transformation to improve patient outcomes, streamline processes, and reduce costs. (ended 2022)

Association of Community Cancer Centers. Dr. Phillips served on the ACCC policy advisory board (ended 2021)

DeciBio Consulting. Dr Phillips served on a one-time advisory board on mult-cancer early detection tests (2021)

Roche Diagnostics. Dr. Phillips provided a one-time review of a clinical genomic profiling evidence assessment tool (2021)

Education
10/2022 - Diversity, Equity, and Inclusion Champion Training, University of California
Post-doctoral fellowship, 1993 - , University of California
PhD, 1991 - Policy Analysis and Health Economics, University of California
MPA, - Public Administration, Kennedy School of Government Harvard University
BA, - Psychology with High Honors, University of Texas
Honors and Awards
  • Standing Member of National Academy of Medicine Roundtable on Genomics and Precision Medicine, National Academy of Medicine, 2021
  • Named in top 2% of authors for career-long citations in field and in top 100,000 of all researchers, Ioannidis et al, PlosBiology 2020; Baas et al,Mendeley Data 2021, 2020-2021
  • Dean's Awards For Outstanding Teaching (multiple), UCSF, 2019-2021
  • Honorary Lectureship, University of British Columbia, 2018
  • Honorary Lectureship, U of Maryland, 2017
  • Rockefeller Foundation Residency, Bellagio Center Italy, 2016
  • Most cited article award, Research Triangle Institute, 2010
  • 50 Most Cited HIV Behavioral Researchers in Past Decade, Univ of CT, 2003
  • Article in New England Journal of Medicine contributed to FDA decision to approve home HIV test, 1996
  • UC Berkeley Graduate Fellowship, UC Berkeley, 1987-1988
Websites
Publications

  1. Phillips KA. Open Access Publication at a Crossroads-Implications for Researchers and Beyond. JAMA health forum 2024. PMID: 39422887


  2. Deverka PA, Lin GA, Phillips KA. Payer Coverage Considerations for Alzheimer Disease Blood-Based Biomarker Tests. JAMA 2024. PMID: 39348131


  3. Lin GA, Coffman JM, Phillips KA. State Biomarker Testing Insurance Coverage Laws-Reply. JAMA 2024. PMID: 39264592


  4. Chen C, Douglas MP, Ragavan MV, Phillips KA, Jansen JP. Clinical Validity and Utility of Circulating Tumor DNA (ctDNA) Testing in Advanced Non-small Cell Lung Cancer (aNSCLC): A Systematic Literature Review and Meta-analysis. Molecular diagnosis & therapy 2024. PMID: 39093546


  5. Lin GA, Coffman JM, Phillips KA. The State of State Biomarker Testing Insurance Coverage Laws. JAMA 2024. PMID: 38739406


  6. Marshall DA, Hua N, Buchanan J, Christensen KD, Frederix GWJ, Goranitis I, Ijzerman M, Jansen JP, Lavelle TA, Regier DA, Smith HS, Ungar WJ, Weymann D, Wordsworth S, Phillips KA. Paving the path for implementation of clinical genomic sequencing globally: Are we ready? Health Affairs Scholar 2024. PMID: 38783891


  7. Phillips KA. Six months, strong impact. Health Affairs Scholar 2024. PMID: 38756393


  8. Chen C, Douglas MP, Ragavan MV, Phillips KA, Jansen JP. Clinical validity and utility of circulating tumor DNA (ctDNA) testing in advanced non-small cell lung cancer (aNSCLC): a systematic literature review and meta-analysis. medRxiv : the preprint server for health sciences 2023. PMID: 37961510


  9. Jansen JP, Ragavan MV, Chen C, Douglas MP, Phillips KA. The health inequality impact of liquid biopsy to inform first-line treatment of advanced non-small cell lung cancer - a distributional cost-effectiveness analysis. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2023. PMID: 37741446


  10. Lin GA, Phillips KA, Fendrick AM. Reading the crystal ball: Primary care implications while awaiting outcomes for multi-cancer early detection tests. Healthcare (Amsterdam, Netherlands) 2023. PMID: 37598614


  11. Trosman JR, Weldon CB, Kurian AW, Pasquinelli MM, Kircher SM, Martin N, Douglas MP, Phillips KA. Perspectives of private payers on multicancer early-detection tests: informing research, implementation, and policy. Health Affairs Scholar 2023. PMID: 38756840


  12. Phillips KA, Marshall DA, Adler L, Figueroa J, Haeder SF, Hamad R, Hernandez I, Moucheraud C, Nikpay S. Ten health policy challenges for the next 10 years. Health Affairs Scholar 2023. PMID: 38756834


  13. Douglas MP, Ragavan MV, Chen C, Kumar A, Gray SW, Blakely CM, Phillips KA. Private Payer and Medicare Coverage Policies for Use of Circulating Tumor DNA Tests in Cancer Diagnostics and Treatment. Journal of the National Comprehensive Cancer Network : JNCCN 2023. PMID: 37308126


  14. Phillips KA. CMS Coverage With Evidence Development-Challenges and Opportunities for Improvement. JAMA health forum 2022. PMID: 36218935


  15. Weldon CB, Trosman JR, Liang SY, Douglas MP, Scheuner MT, Kurian A, Schaa KL, Roscow B, Erwin D, Phillips KA. Genetic counselors' experience with reimbursement and patient out-of-pocket cost for multi-cancer gene panel testing for hereditary cancer syndromes. Journal of genetic counseling 2022. PMID: 35900261


  16. Deverka PA, Douglas MP, Phillips KA. Multicancer Screening Tests: Anticipating And Addressing Considerations For Payer Coverage And Patient Access. 2022. PMID: 35254936


  17. Arias JJ, Lin GA, Tyler AM, Douglas MP, Phillips KA. Geriatricians' Perspectives on the Multiple Dimensions of Utility of Genetic Testing for Alzheimer's Disease: A Qualitative Study. Journal of Alzheimer's disease : JAD 2022. PMID: 35871355


  18. Phillips KA, Trosman JR, Douglas MP, Gelb BD, Ferket BS, Hindorff LA, Slavotinek AM, Berg JS, Russell HV, Devine B, Greve V, Smith HS. US private payers' perspectives on insurance coverage for genome sequencing versus exome sequencing: A study by the Clinical Sequencing Evidence-Generating Research Consortium (CSER). 2021. PMID: 34906461


  19. Douglas MP, Lin GA, Trosman JR, Phillips KA. Hereditary cancer panel testing challenges and solutions for the latinx community: costs, access, and variants. 2021. PMID: 34743282


  20. Lin GA, Trosman JR, Douglas MP, Weldon CB, Scheuner MT, Kurian A, Phillips KA. Influence of payer coverage and out-of-pocket costs on ordering of NGS panel tests for hereditary cancer in diverse settings. Journal of genetic counseling 2021. PMID: 34231930


  21. Arias JJ, Phillips KA, Karlawish J. Developing an Economic and Policy Research Agenda for Blood Biomarkers of Neurodegenerative Diseases. JAMA health forum 2021. PMID: 36218772


  22. Scheuner MT, Douglas MP, Sales P, Ackerman SL, Phillips KA. Laboratory business models and practices: implications for availability and access to germline genetic testing. Genetics in medicine : official journal of the American College of Medical Genetics 2021. PMID: 33958748


  23. Phillips KA, Douglas MP, Wordsworth S, Buchanan J, Marshall DA. Availability and funding of clinical genomic sequencing globally. 2021. PMID: 33574068


  24. Arias JJ, Tyler AM, Douglas MP, Phillips KA. Private payer coverage policies for ApoE-e4 genetic testing. 2021. PMID: 33420342


  25. Phillips KA, Douglas MP, Marshall DA. Expanding Use of Clinical Genome Sequencing and the Need for More Data on Implementation. 2020. PMID: 33104159


  26. Douglas MP, Gray SW, Phillips KA. Private Payer and Medicare Coverage for Circulating Tumor DNA Testing: A Historical Analysis of Coverage Policies From 2015 to 2019. Journal of the National Comprehensive Cancer Network : JNCCN 2020. PMID: 32634780


  27. Phillips KA. Methods for Moving the Evaluation of Precision Medicine Into Practice and Policy. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2020. PMID: 32389216


  28. Marshall DA, Grazziotin LR, Regier DA, Wordsworth S, Buchanan J, Phillips K, Ijzerman M. Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation Modeling. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2020. PMID: 32389221


  29. Deverka PA, Douglas MP, Phillips KA. Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2020. PMID: 32389218


  30. Mackay ZP, Dukhovny D, Phillips KA, Beggs AH, Green RC, Parad RB, Christensen KD. Quantifying Downstream Healthcare Utilization in Studies of Genomic Testing. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2020. PMID: 32389220


  31. Trosman JR, Douglas MP, Liang SY, Weldon CB, Kurian AW, Kelley RK, Phillips KA. Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2020. PMID: 32389219


  32. Phillips KA, Marshall DA, Kurian AW. Can precision medicine help achieve the goal of reducing care when the risks exceed the benefits? Personalized medicine 2019. PMID: 31552799


  33. Trosman JR, Weldon CB, Slavotinek A, Norton ME, Douglas MP, Phillips KA. Perspectives of US private payers on insurance coverage for pediatric and prenatal exome sequencing: Results of a study from the Program in Prenatal and Pediatric Genomic Sequencing (P3EGS). Genetics in medicine : official journal of the American College of Medical Genetics 2019. PMID: 31501586


  34. Phillips KA, Trosman JR, Douglas MP. Emergence of Hybrid Models of Genetic Testing Beyond Direct-to-Consumer or Traditional Labs. JAMA 2019. PMID: 31145414


  35. Zakinova A, Long-Boyle JR, French D, Croci R, Wilson L, Phillips KA, Kroetz DL, Shin J, Tamraz B. A Practical First Step Using Needs Assessment and a Survey Approach to Implementing a Clinical Pharmacogenomics Consult Service. Journal of the American College of Clinical Pharmacy : JAACP 2018. PMID: 32391517


  36. Phillips KA, Douglas MP. The Global Market for Next-Generation Sequencing Tests Continues Its Torrid Pace. The Journal of precision medicine 2018. PMID: 32149190


  37. Phillips KA. Assessing the Value of Next-Generation Sequencing Technologies: An Introduction. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2018. PMID: 30224105


  38. Christensen KD, Phillips KA, Green RC, Dukhovny D. Cost Analyses of Genomic Sequencing: Lessons Learned from the MedSeq Project. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2018. PMID: 30224109


  39. Phillips KA, Deverka PA, Marshall DA, Wordsworth S, Regier DA, Christensen KD, Buchanan J. Methodological Issues in Assessing the Economic Value of Next-Generation Sequencing Tests: Many Challenges and Not Enough Solutions. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2018. PMID: 30224106


  40. Trosman JR, Weldon CB, Gradishar WJ, Benson AB, Cristofanilli M, Kurian AW, Ford JM, Balch A, Watkins J, Phillips KA. From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2018. PMID: 30224110


  41. Douglas MP, Parker SL, Trosman JR, Slavotinek AM, Phillips KA. Private payer coverage policies for exome sequencing (ES) in pediatric patients: trends over time and analysis of evidence cited. Genetics in medicine : official journal of the American College of Medical Genetics 2018. PMID: 29997388


  42. Phillips KA. Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning? JAMA 2018. PMID: 29710095


  43. Phillips KA, Deverka PA, Hooker GW, Douglas MP. Genetic Test Availability And Spending: Where Are We Now? Where Are We Going? Health affairs (Project Hope) 2018. PMID: 29733704


  44. Ginsburg GS, Phillips KA. Precision Medicine: From Science To Value. Health affairs (Project Hope) 2018. PMID: 29733705


  45. Phillips KA, Trosman JR, Deverka PA, Quinn B, Tunis S, Neumann PJ, Chambers JD, Garrison LP, Douglas MP, Weldon CB. Insurance coverage for genomic tests. Science (New York, N.Y.) 2018. PMID: 29674586


  46. Christensen KD, Vassy JL, Phillips KA, Blout CL, Azzariti DR, Lu CY, Robinson JO, Lee K, Douglas MP, Yeh JM, Machini K, Stout NK, Rehm HL, McGuire AL, Green RC, Dukhovny D. Short-term costs of integrating whole-genome sequencing into primary care and cardiology settings: a pilot randomized trial. Genetics in medicine : official journal of the American College of Medical Genetics 2018. PMID: 29565423


  47. Marshall DA, Gonzalez JM, Johnson FR, MacDonald KV, Pugh A, Douglas MP, Phillips KA. Corrigendum: What are people willing to pay for whole-genome sequencing information, and who decides what they receive? Volume 20 of Issue 1. Genetics in medicine : official journal of the American College of Medical Genetics 2017. PMID: 29261179


  48. Chambers JD, Saret CJ, Anderson JE, Deverka PA, Douglas MP, Phillips KA. EXAMINING EVIDENCE IN U.S. PAYER COVERAGE POLICIES FOR MULTI-GENE PANELS AND SEQUENCING TESTS. Volume 33 of Issue 4. International journal of technology assessment in health care 2017. PMID: 29065945


  49. Phillips KA, Deverka PA, Trosman JR, Douglas MP, Chambers JD, Weldon CB, Dervan AP. Payer coverage policies for multigene tests. Volume 35 of Issue 7. Nature biotechnology 2017. PMID: 28700544


  50. Marshall DA, MacDonald KV, Robinson JO, Barcellos LF, Gianfrancesco M, Helm M, McGuire A, Green RC, Douglas MP, Goldman MA, Phillips KA. The price of whole-genome sequencing may be decreasing, but who will be sequenced? Volume 14 of Issue 3. Personalized medicine 2017. PMID: 28993792


  51. Phillips KA, Deverka PA, Sox HC, Khoury MJ, Sandy LG, Ginsburg GS, Tunis SR, Orlando LA, Douglas MP. Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research. Volume 19 of Issue 10. Genetics in medicine : official journal of the American College of Medical Genetics 2017. PMID: 28406488


  52. Trosman JR, Weldon CB, Douglas MP, Kurian AW, Kelley RK, Deverka PA, Phillips KA. Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative. Volume 15 of Issue 2. Journal of the National Comprehensive Cancer Network : JNCCN 2017. PMID: 28188191


  53. Phillips KA, Douglas MP, Trosman JR, Marshall DA. "What Goes Around Comes Around": Lessons Learned from Economic Evaluations of Personalized Medicine Applied to Digital Medicine. Volume 20 of Issue 1. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2017. PMID: 28212968


  54. Phillips KA. Assessing the Value and Implications of Personalized/Precision Medicine and the "Lessons Learned" for Emerging Technologies: An Introduction. Volume 20 of Issue 1. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2017. PMID: 28212965


  55. Trosman JR, Weldon CB, Douglas MP, Deverka PA, Watkins JB, Phillips KA. Decision Making on Medical Innovations in a Changing Health Care Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies. Volume 20 of Issue 1. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2017. PMID: 28212967


  56. Dervan AP, Deverka PA, Trosman JR, Weldon CB, Douglas MP, Phillips KA. Payer decision making for next-generation sequencing-based genetic tests: insights from cell-free DNA prenatal screening. Volume 19 of Issue 5. Genetics in medicine : official journal of the American College of Medical Genetics 2016. PMID: 27657682


  57. Marshall DA, Gonzalez JM, Johnson FR, MacDonald KV, Pugh A, Douglas MP, Phillips KA. What are people willing to pay for whole-genome sequencing information, and who decides what they receive? Volume 18 of Issue 12. Genetics in medicine : official journal of the American College of Medical Genetics 2016. PMID: 27253734


  58. Phillips KA, Schleifer D, Hagelskamp C. Most Americans Do Not Believe That There Is An Association Between Health Care Prices And Quality Of Care. Volume 35 of Issue 4. Health affairs (Project Hope) 2016. PMID: 27044965


  59. Clain E, Trosman JR, Douglas MP, Weldon CB, Phillips KA. Availability and payer coverage of BRCA1/2 tests and gene panels. Volume 33 of Issue 9. Nature biotechnology 2015. PMID: 26348951


  60. Douglas MP, Ladabaum U, Pletcher MJ, Marshall DA, Phillips KA. Economic evidence on identifying clinically actionable findings with whole-genome sequencing: a scoping review. Volume 18 of Issue 2. Genetics in medicine : official journal of the American College of Medical Genetics 2015. PMID: 25996638


  61. Phillips KA, Ladabaum U, Pletcher MJ, Marshall DA, Douglas MP. Key emerging themes for assessing the cost-effectiveness of reporting incidental findings. Volume 17 of Issue 4. Genetics in medicine : official journal of the American College of Medical Genetics 2015. PMID: 25835195


  62. Trosman JR, Weldon CB, Kelley RK, Phillips KA. Challenges of coverage policy development for next-generation tumor sequencing panels: experts and payers weigh in. Volume 13 of Issue 3. Journal of the National Comprehensive Cancer Network : JNCCN 2015. PMID: 25736008


  63. Foster DG, Biggs MA, Phillips KA, Grindlay K, Grossman D. Potential public sector cost-savings from over-the-counter access to oral contraceptives. Volume 91 of Issue 5. Contraception 2015. PMID: 25732570


  64. Knight SJ, Mohamed AF, Marshall DA, Ladabaum U, Phillips KA, Walsh JM. Value of Genetic Testing for Hereditary Colorectal Cancer in a Probability-Based US Online Sample. Medical decision making : an international journal of the Society for Medical Decision Making 2015. PMID: 25589525


  65. Garfeld S, Douglas MP, MacDonald KV, Marshall DA, Phillips KA. Consumer familiarity, perspectives and expected value of personalized medicine with a focus on applications in oncology. Volume 12 of Issue 1. Personalized medicine 2015. PMID: 25620993


  66. Phillips KA, Pletcher MJ, Ladabaum U. Is the ``$1000 Genome'' really $1000? Understanding the full benefits and costs of genomic sequencing. Volume 23 of Issue 3. Technology and health care : official journal of the European Society for Engineering and Medicine 2015. PMID: 25669213


  67. Phillips KA, Trosman JR, Kelley RK, Pletcher MJ, Douglas MP, Weldon CB. Genomic sequencing: assessing the health care system, policy, and big-data implications. Volume 33 of Issue 7. Health affairs (Project Hope) 2014. PMID: 25006153


  68. Balakrishnan N, Pritchard J, Ericson M, Grindem C, Phillips K, Jennings S, Mathews K, Tran H, Birkenheuer AJ, Breitschwerdt EB. Prostatitis, steatitis, and diarrhea in a dog following presumptive flea-borne transmission of Bartonella henselae. Volume 52 of Issue 9. Journal of clinical microbiology 2014. PMID: 24920774


  69. Phillips KA, Ann Sakowski J, Trosman J, Douglas MP, Liang SY, Neumann P. The economic value of personalized medicine tests: what we know and what we need to know. Volume 16 of Issue 3. Genetics in medicine : official journal of the American College of Medical Genetics 2013. PMID: 24232413


  70. Phillips KA, Sakowski JA, Liang SY, Ponce NA. Economic Perspectives on Personalized Health Care and Prevention. Forum for health economics & policy 2013. PMID: 31419875


  71. Wang G, Kuppermann M, Kim B, Phillips KA, Ladabaum U. Influence of patient preferences on the cost-effectiveness of screening for lynch syndrome. Volume 8 of Issue 3 Suppl. Journal of oncology practice 2012. PMID: 22942831


  72. Beattie MS, Wang G, Phillips KA. Differences in US healthcare coverage policies in BRCA testing and potential implications. Personalized medicine 2012. PMID: 29783285


  73. Wang G, Beattie MS, Ponce NA, Phillips KA. Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling. Volume 13 of Issue 12. Genetics in medicine : official journal of the American College of Medical Genetics 2011. PMID: 21844812


  74. Elkin EB, Marshall DA, Kulin NA, Ferrusi IL, Hassett MJ, Ladabaum U, Phillips KA. Economic evaluation of targeted cancer interventions: critical review and recommendations. Volume 13 of Issue 10. Genetics in medicine : official journal of the American College of Medical Genetics 2011. PMID: 21637102


  75. Liang SY, Phillips KA, Wang G, Keohane C, Armstrong J, Morris WM, Haas JS. Tradeoffs of using administrative claims and medical records to identify the use of personalized medicine for patients with breast cancer. Volume 49 of Issue 6. Medical care 2011. PMID: 21422962


  76. Haas JS, Phillips KA, Liang SY, Hassett MJ, Keohane C, Elkin EB, Armstrong J, Toscano M. Genomic testing and therapies for breast cancer in clinical practice. Volume 7 of Issue 3 Suppl. Journal of oncology practice 2011. PMID: 21886507


  77. Trosman JR, Van Bebber SL, Phillips KA. Health technology assessment and private payers' coverage of personalized medicine. Volume 7 of Issue 3 Suppl. Journal of oncology practice 2011. PMID: 21886515


  78. Trosman JR, Van Bebber SL, Phillips KA. Health technology assessment and private payers's coverage of personalized medicine. Volume 17 Suppl 5 Developing. The American journal of managed care 2011. PMID: 21711078


  79. Johnson FR, Mohamed AF, Ozdemir S, Marshall DA, Phillips KA. How does cost matter in health-care discrete-choice experiments? Volume 20 of Issue 3. Health economics 2011. PMID: 20217834


  80. Kelley RK, Van Bebber SL, Phillips KA, Venook AP. Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. Volume 9 of Issue 1. Journal of the National Comprehensive Cancer Network : JNCCN 2011. PMID: 21233242


  81. Trosman JR, Van Bebber SL, Phillips KA. Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay. Volume 6 of Issue 5. Journal of oncology practice 2010. PMID: 21197187


  82. Van Bebber SL, Trosman JR, Liang SY, Wang G, Marshall DA, Knight S, Phillips KA. Capacity building for assessing new technologies: approaches to examining personalized medicine in practice. Volume 7 of Issue 4. Personalized medicine 2010. PMID: 21857867


  83. Marshall DA, Johnson FR, Kulin NA, Ozdemir S, Walsh JM, Marshall JK, Van Bebber S, Phillips KA. How do physician assessments of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a stated-choice survey. Volume 18 of Issue 12. Health economics 2009. PMID: 19191268


  84. Phillips KA, Marshall DA, Haas JS, Elkin EB, Liang SY, Hassett MJ, Ferrusi I, Brock JE, Van Bebber SL. Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Volume 115 of Issue 22. Cancer 2009. PMID: 19753618


  85. Ferrusi IL, Marshall DA, Kulin NA, Leighl NB, Phillips KA. Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses. Volume 6 of Issue 2. Personalized medicine 2009. PMID: 20668661


  86. Phillips KA, Liang SY, Van Bebber S. Challenges to the translation of genomic information into clinical practice and health policy: Utilization, preferences and economic value. Volume 10 of Issue 3. Current opinion in molecular therapeutics 2008. PMID: 18535933


  87. Haas JS, Fitzmaurice G, Brawarsky P, Liang SY, Hiatt RA, Klabunde CN, Brown ML, Phillips KA. Association of regional variation in primary care physicians' colorectal cancer screening recommendations with individual use of colorectal cancer screening. Volume 4 of Issue 4. Preventing chronic disease 2007. PMID: 17875265


  88. Issa AM, Phillips KA, Van Bebber S, Nidamarthy HG, Lasser KE, Haas JS, Alldredge BK, Wachter RM, Bates DW. Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends. Current drug safety 2007. PMID: 18690965


  89. Marshall DA, Johnson FR, Phillips KA, Marshall JK, Thabane L, Kulin NA. Measuring patient preferences for colorectal cancer screening using a choice-format survey. Volume 10 of Issue 5. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2007. PMID: 17888107


  90. Van Bebber SL, Liang SY, Phillips KA, Marshall D, Walsh J, Kulin N. Valuing personalized medicine: willingness to pay for genetic testing for colorectal cancer risk. Personalized medicine 2007. PMID: 29788665


  91. Phillips KA, Liang SY, Ladabaum U, Haas J, Kerlikowske K, Lieberman D, Hiatt R, Nagamine M, Van Bebber SL. Trends in colonoscopy for colorectal cancer screening. Volume 45 of Issue 2. Medical care 2007. PMID: 17224779


  92. Afable-Munsuz A, Gould H, Stewart F, Phillips KA, Van Bebber SL, Moore C. Provider practice models for and costs of delivering medication abortion -- evidence from 11 US abortion care settings. Volume 75 of Issue 1. Contraception 2006. PMID: 17161124


  93. Phillips KA, Van Bebber SL, Issa AM. Initial development of an evidence base for personalized medicine's translation to clinical practice and health policy. Personalized medicine 2006. PMID: 29788589


  94. Issa AM, Todd Weiss L, Tufail W, Phillips KA, Van Bebber SL. Innovation in personalized medicine: BiDil® as a case study for integrating clinical and policy developments. Personalized medicine 2006. PMID: 29788596


  95. Van Bebber SL, Keegan HL, Phillips KA, Issa AM. Novel personalized medicine technology: UGT1A1 testing for irinotecan as a case study. Personalized medicine 2006. PMID: 29788595


  96. Liang SY, Phillips KA, Nagamine M, Ladabaum U, Haas JS. Rates and predictors of colorectal cancer screening. Volume 3 of Issue 4. Preventing chronic disease 2006. PMID: 16978492


  97. Keenan PS, Neumann PJ, Phillips KA. Biotechnology and Medicare's new technology policy: lessons from three case studies. Volume 25 of Issue 5. Health affairs (Project Hope) 2006. PMID: 16966721


  98. Phillips KA. The intersection of biotechnology and pharmacogenomics: health policy implications. Volume 25 of Issue 5. Health affairs (Project Hope) 2006. PMID: 16966723


  99. Phillips KA, Van Bebber S, Marshall D, Walsh J, Thabane L. A review of studies examining stated preferences for cancer screening. Volume 3 of Issue 3. Preventing chronic disease 2006. PMID: 16776876


  100. Phillips KA, Van Bebber SL. Regulatory perspectives on pharmacogenomics: a review of the literature on key issues faced by the United States Food and Drug Administration. Volume 63 of Issue 3. Medical care research and review : MCRR 2006. PMID: 16651395


  101. Phillips KA, Van Bebber S, Issa AM. Diagnostics and biomarker development: priming the pipeline. Volume 5 of Issue 6. Nature reviews. Drug discovery 2006. PMID: 16718275


  102. Gellad WF, Huskamp HA, Phillips KA, Haas JS. How the new medicare drug benefit could affect vulnerable populations. Volume 25 of Issue 1. Health affairs (Project Hope) 2006. PMID: 16403761


  103. Van Bebber SL, Phillips KA, Weitz TA, Gould H, Stewart F. Patient costs for medication abortion: results from a study of five clinical practices. Volume 16 of Issue 1. Women's health issues : official publication of the Jacobs Institute of Women's Health 2006. PMID: 16487919


  104. Phillips KA, Ackerman MJ, Sakowski J, Berul CI. Cost-effectiveness analysis of genetic testing for familial long QT syndrome in symptomatic index cases. Volume 2 of Issue 12. Heart rhythm 2005. PMID: 16360080


  105. Phillips KA, Liang SY, Haas JS, Stebbins M, Alldredge BK. Prescription drug dispensing limits and patterns. Volume 18 of Issue 7. Managed care interface 2005. PMID: 16060485


  106. Phillips KA, Van Bebber SL. Measuring the value of pharmacogenomics. Volume 4 of Issue 6. Nature reviews. Drug discovery 2005. PMID: 15915153


  107. Phillips KA, Van Bebber SL. A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. Volume 5 of Issue 8. Pharmacogenomics 2004. PMID: 15584880


  108. Baker LC, Phillips KA, Haas JS, Liang SY, Sonneborn D. The effect of area HMO market share on cancer screening. Volume 39 of Issue 6 Pt 1. Health services research 2004. PMID: 15533185


  109. Haggstrom DA, Phillips KA, Liang SY, Haas JS, Tye S, Kerlikowske K. Variation in screening mammography and Papanicolaou smear by primary care physician specialty and gatekeeper plan (United States). Volume 15 of Issue 9. Cancer causes & control : CCC 2004. PMID: 15577290


  110. Phillips KA, Veenstra DL, Ramsey SD, Van Bebber SL, Sakowski J. Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs. Volume 10 of Issue 7 Pt 1. The American journal of managed care 2004. PMID: 15298364


  111. Haas JS, Phillips KA, Sonneborn D, McCulloch CE, Baker LC, Kaplan CP, Pérez-Stable EJ, Liang SY. Variation in access to health care for different racial/ethnic groups by the racial/ethnic composition of an individual's county of residence. Volume 42 of Issue 7. Medical care 2004. PMID: 15213496


  112. Phillips KA, Haas JS, Liang SY, Baker LC, Tye S, Kerlikowske K, Sakowski J, Spetz J. Are gatekeeper requirements associated with cancer screening utilization? Volume 39 of Issue 1. Health services research 2004. PMID: 14965082


  113. Liang SY, Phillips KA, Tye S, Haas JS, Sakowski J. Does patient cost sharing matter? Its impact on recommended versus controversial cancer screening services. Volume 10 of Issue 2 Pt 1. The American journal of managed care 2004. PMID: 15011810


  114. Tye S, Phillips KA, Liang SY, Haas JS. Moving beyond the typologies of managed care: the example of health plan predictors of screening mammography. Volume 39 of Issue 1. Health services research 2004. PMID: 14965083


  115. Phillips KA, Stotland NE, Liang SY, Spetz J, Haas JS, Oren E. Out-of-pocket expenditures for oral contraceptives and number of packs per purchase. Volume 59 of Issue 1. Journal of the American Medical Women's Association (1972) 2004. PMID: 14768985


  116. Haas JS, Lee LB, Kaplan CP, Sonneborn D, Phillips KA, Liang SY. The association of race, socioeconomic status, and health insurance status with the prevalence of overweight among children and adolescents. Volume 93 of Issue 12. American journal of public health 2003. PMID: 14652342


  117. Phillips KA. Important step forward in HIV-testing technologies [correction of technolgies]. Volume 25 of Issue 2. American journal of preventive medicine 2003. PMID: 12880887


  118. Phillips KA, Veenstra D, Van Bebber S, Sakowski J. An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics. Volume 4 of Issue 3. Pharmacogenomics 2003. PMID: 12718713


  119. Haas JS, Phillips KA, Baker LC, Sonneborn D, McCulloch CE. Is the prevalence of gatekeeping in a community associated with individual trust in medical care? Volume 41 of Issue 5. Medical care 2003. PMID: 12719690


  120. Phillips KA, Chen JL. Willingness to use instant home HIV tests: data from the California Behavioral Risk Factor Surveillance Survey. Volume 24 of Issue 4. American journal of preventive medicine 2003. PMID: 12726872


  121. Phillips KA, Bayer R, Chen JL. New Centers for Disease Control and Prevention's guidelines on HIV counseling and testing for the general population and pregnant women. Volume 32 of Issue 2. Journal of acquired immune deficiency syndromes (1999) 2003. PMID: 12571528


  122. Phillips KA, Spetz J, Haas JS. Viagra and contraceptives. Volume 22 of Issue 1. Health affairs (Project Hope) 2003. PMID: 12528859


  123. Phillips KA, Maddala T, Johnson FR. Measuring preferences for health care interventions using conjoint analysis: an application to HIV testing. Volume 37 of Issue 6. Health services research 2002. PMID: 12546292


  124. Phillips KA, Johnson FR, Maddala T. Measuring what people value: a comparison of "attitude" and "preference" surveys. Volume 37 of Issue 6. Health services research 2002. PMID: 12546291


  125. Haas JS, Phillips KA, Sonneborn D, McCulloch CE, Liang SY. Effect of managed care insurance on the use of preventive care for specific ethnic groups in the United States. Volume 40 of Issue 9. Medical care 2002. PMID: 12218765


  126. Oren E, McCart G, Phillips KA. Evaluating the potential impact of pharmacogenomics on ADRs. Volume 8 of Issue 4. Journal of managed care pharmacy : JMCP 2002. PMID: 14613422


  127. Phillips KA, Chen JL. Impact of the U.S. panel on cost-effectiveness in health and medicine. Volume 22 of Issue 2. American journal of preventive medicine 2002. PMID: 11818178